Track reimbursement lists, DRG payment reform, procurement rules and pharmaceutical and medical device regulation — with concise summaries and expert commentary from HERAC’s health economists.
Each entry summarises what the policy does, who it affects, its status and HERAC’s take on the implications for market access.
| Policy | Area | Status | Why it matters |
|---|---|---|---|
| Reimbursement list for chemical drugs, biologicals, radiopharmaceuticals and tracersDraft Circular · Ministry of Health | Reimbursement | Consultation | Defines which medicines social health insurance pays for, and on what conditions. |
| DRG-based payment methodologyPlan & draft data regulation · Ministry of Health | Provider payment | In development | Shifts hospital incentives from fee-for-service to case-based budgets — affects uptake of high-cost therapies. |
| Medical Device LawDraft law · Ministry of Health | Medical devices | Drafting | Sets post-market surveillance and the role of HTA and health insurance data for devices. |
| Supplementary health insurancePolicy orientation · Department of Health Insurance | Health financing | Policy study | Could open co-financing routes for services and products beyond the basic benefit package. |
| Amended Law on PharmacyLaw · National Assembly | Pharmaceutical law | Adopted | Updates registration, pricing and supply rules for medicines. |
Every Monday: new legal documents, HTA and reimbursement news, procurement results and upcoming consultations — summarised and linked to official sources.
Research summary →
Free weekly email for market access, HEOR, medical and public affairs teams working on Vietnam. Unsubscribe anytime.
The Monitor is published by the Health Economics Research and Assessment Center (HERAC), an independent science and technology organization and member of the Vietnam Medical Association. Summaries are written by HERAC staff from official documents and public sources, always linked to the original.
Commentary reflects HERAC’s independent scientific view. Sponsored work is never presented as editorial content, and any industry involvement in research we summarise is disclosed.